-
Most Popular
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Here’s Why You Should Buy More CELG Shares After Earnings Dip
Third quarter show that CELG continues to grow its business, it continues to make product people like and that Revlimid hasn't peaked yet.
Gilead Sciences, Inc. – GILD Stock Catches the Bears Off Guard Again
Biotechnology stocks as a group are not yet out of the woods, but single-name stocks like GILD stock look promising right now.
Trade of the Day: Biotech Double – Mannkind (MNKD) and PDL BioPharma (PDLI)
Biotech stocks got hit hard in recent weeks as concerns about prescription drug prices mounted.
AZN: Why AstraZeneca’s Current Dip Is a Buying Opportunity
Astrazeneca has been investing aggressively in immuno-oncology, which will make AZN stock much more attractive in the long run.
3 of the Best Actively Managed Fidelity Funds
Fidelity funds offer a broad selection of low-cost, no-load, actively-managed funds. Here are 3 of their best.
AMGN Stock: The Dark Underbelly of Amgen Earnings
Amagen reported a stellar-looking earnings report, but a lot of its revenue increases were due to price hikes and not higher adoption.
Big Opportunities in Big Pharma
There’s a lot going on in biotech right now, which means there are plenty of opportunities worth looking into.
GILD Stock: 2 Big Things You Should Know About Gilead Sciences
Gilead is walloping its biotech peers on its way to cornering the HCV market. With improving sales, income and better cash management, GILD stock is a reliable long-term investment.
The Big Winners in Teva’s Acquisition of Allergan Generics
Teva and Allergan benefit the most from the $40 billion deal, but prospects remain bright for Mylan, Perrigo and, indeed, the wider sector.
Short the IBB ETF While Pressure Builds
The price action of the Nasdaq Biotechnology Index (IBB) is flashing warning signs for large-cap biotech.
BioMarin (BMRN) Stock Soars, Taking IBB With It
BioMarin (BMRN) stock is soaring on Thursday after promising Phase 2 trial data on a dwarfism drug, vosoritide. The IBB ETF is rallying, too.
How to Forecast Pharma Stocks (PFE, RAD, JNJ)
Pharma companies like PFE, JNJ and RAD are very tricky for fundamental analysts. But principles of relative-strength analysis should still be applied to confirm the fundamental factors.
Can Biotech Stocks Break Out, Or Will They Break Down?
Biotech stocks are a step up from lottery tickets: Fortunes made and lost on the clinical results and regulatory approval. Will they break down or break out?
Trade of the Day: Pfizer (PFE)
PFE is bouncing off support -- and, as a perennial powerhouse, we expect the stock to move back up toward its recent highs.
Did Alexion Jump the Shark With Its Synageva Bid? (ALXN, GEVA)
While ALXN seems to have overpaid for GEVA on the surface. However, investors can expect to see the benefits over the long-term.
